Developing a center for comparative effectiveness information

被引:111
作者
Wilensky, Gail R.
机构
[1] Project HOPE, Bethesda, MD
关键词
D O I
10.1377/hlthaff.25.w572
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Interest in objective, credible comparative clinical effectiveness information has been growing in the United States, both by those who support competitive behavior in health care and by those who support administered pricing. The Medicare drug benefit has heightened interest in better information, although the potential payoff is even greater for medical procedures than for drugs, since procedures account for more of the health care dollar. Careful consideration needs to be given regarding the appropriate structure, placement, financing, and function of an agency devoted to comparative effectiveness if it is to achieve its objective: a mechanism to support better decision making in health care.
引用
收藏
页码:W572 / W585
页数:14
相关论文
共 9 条
[1]  
BALEKDJIAN D, 2003, MANAGED CARE MANDATE
[2]  
Ellwood P M, 1992, Health Econ, V1, P149, DOI 10.1002/hec.4730010303
[3]  
*I MED, 2006, ROUNDT EV BAS MED
[4]  
Mitchell A, 1996, MED CARE, V34, pDS216
[5]   Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom [J].
Morgan, SG ;
McMahon, M ;
Mitton, C ;
Roughead, E ;
Kirk, R ;
Kanavos, P ;
Menon, D .
HEALTH AFFAIRS, 2006, 25 (02) :337-347
[6]   Evidence-based and value-based formulary guidelines [J].
Neumann, PJ .
HEALTH AFFAIRS, 2004, 23 (01) :124-134
[7]  
*REG GROUP, 2002, FAM SUBM GUID VERS 2
[8]  
*REG GROUP, 1997, GUID SUBM CLIN EC DA
[9]   Perspective - An information infrastructure for the pharmaceutical market [J].
Reinhardt, UE .
HEALTH AFFAIRS, 2004, 23 (01) :107-112